In the international “ALL-BFM Registry”, researchers analyse data from young patients with acute lymphoblastic leukaemia in order to ensure high-quality care and, among other things, support the planning of clinical trials. The research project is now open to children and adolescents in Switzerland affected by the disease.
Acute lymphoblastic leukaemia (ALL) accounts for around one third of all cancers diagnosed in childhood and adolescence. Leukaemias are malignant diseases of the bone marrow, where blood is produced. Fortunately, more than 90% of cases of ALL can now be cured – thanks to intensive research. However, the treatments have severe side-effects, and long-term consequences are not uncommon. Relapses can also occur. Continued research is therefore a top priority.
An international research project now aims to improve the data available on this form of leukaemia through a comprehensive data collection, the “ALL-BFM Registry”. To this end, researchers are collecting and analysing medical data from children and adolescents with ALL across several countries.
Â
A foundation for improving leukaemia treatment
The data from the research project help scientists improve the diagnosis and treatment of children and adolescents with ALL and ensure the quality of care. The “ALL-BFM Registry” provides a basis for new clinical trials and research projects – ultimately benefiting future patients. However, researchers can also identify participants for whom a clinical study is already available. Taking part in a study is beneficial for the children and adolescents concerned.
The Swiss Paediatric Oncology Group (SPOG) is pleased that the “ALL-BFM Registry” is now open in Switzerland.
Further information: ALL-BFM Registry
Brigitte Casanova
Brigitte Casanova supports SPOG communication projects; as a Germanist, she complements the science-oriented team at the Coordination Center.
More articles from Brigitte Casanova 
